Technical Data
B0003-05
Bacillus anthracis (Anthrax)
Description:
Anthrax toxin plays a major role in the pathogenesis of anthrax. Virulent strains of Bacillus anthracis produce a complex exotoxin with 3 distinct antigenic components: the edema factor (EF), the protective antigen or binding domain (PA), and the lethal factor (LF).

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Recommended Pair:
Suitable for use as the capture or solid phase antibody.
Matched to B0003-05D or B0003-05E as the detection or conjugate (label) antibody.

Hybridoma:
Sp2/0 myeloma cells with spleen cells from Balb/c mice.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG11.B.10Affinity Purified
SizeStorageShippingSourceHost
500ug-20CBlue IceMouse
Concentration:
~1mg/ml
Immunogen:
Purified protective antigen from inactivated Bacillus anthracis culture (vaccine strain STI-1)
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide.
Specificity:
Recognizes protective antigen Bacillus anthracis. Does not crossreact with lethal factor antigen of B. anthracis, Y. pestis, F. tularensis or Toxoplasma gondii.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.